SCHEMBL4069498

SCHEMBL4069498

CC(=O)c1nccc2c1[nH]c1ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.63
ACHE P22303 1/20 0.63
DYRK1A Q13627 1/20 0.63
TDO2 P48775 4/20 0.59
KDM4E B2RXH2 4/20 0.59
MEN1 O00255 3/20 0.59
MAPT P10636 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPK1 P28482 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
ALDH1A1 P00352 2/20 0.59
GABRP O00591 1/20 0.59
GABRD O14764 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
GABRA1 P14867 1/20 0.59
HPGD P15428 1/20 0.59
TSHR P16473 1/20 0.59
GABRB1 P18505 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29927826 1.00 BCHE (0.63) BCHEACHEDYRK1ATDO2KDM4E
SCHEMBL28661144 0.87 BCHE (0.69) BCHETDO2KDM4EMEN1MAPT
SCHEMBL933660 0.86 BCHE (0.60) BCHEDYRK1ATDO2KDM4EMEN1
SCHEMBL29611964 0.84 BRAF (0.61) BCHETDO2KDM4EMEN1MAPT
SCHEMBL1218770 0.84 BRAF (0.61) BCHETDO2KDM4EMEN1MAPT
Hydrochloric Acid SCHEMBL6239184 0.84 BCHE (0.59) BCHEDYRK1ATDO2KDM4EMEN1
SCHEMBL5080656 0.84 BCHE (0.55) BCHEACHEDYRK1ATDO2KDM4E
SCHEMBL27929500 0.83 BCHE (0.57) BCHETDO2KDM4EMEN1MAPT
Hydrochloric Acid SCHEMBL27734884 0.82 BCHE (0.54) BCHEACHEDYRK1ATDO2KDM4E
SCHEMBL5850711 0.82 BCHE (0.56) BCHETDO2KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2926119-B1 METHOD OF MARKING OF MATERIAL, MARKED MATERIAL AND METHOD FOR AUTHENTICATING A MATERIAL SICPA HOLDING SA (CH) 2023-02-22 EP claimed
CN-109528718-B Medicine for treating cervical cancer and application thereof 孙凤永 2020-11-24 CN claimed
EP-2926119-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION Sicpa Holding SA (CH) 2015-10-07 EP claimed
US-20140154813-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION SICPA HOLDING SA (CH) 2014-06-05 US claimed
WO-2014083145-A1 MARKING OF MATERIAL, MARKED MATERIAL AND PROCESS OF AUTHENTICATION OR DILUTION DETERMINATION SICPA HOLDING SA (CH) 2014-06-05 WO claimed
CN-103374056-A 1-Acetyl-beta-carboline-3-formyl amino-acid benzyl ester, and synthesis and application thereof UNIV CAPITAL MEDICAL SCIENCES 2013-10-30 CN claimed
US-8313934-B2 Use of hydrophobic solvent immisible from fermentation broth; hydrocarbon biosynthesis of e.g. biodiesel fuels; kits, vehicles, biofuel product LS9, INC. (US) 2012-11-20 US claimed
US-20090084025-A1 REDUCTION OF THE TOXIC EFFECT OF IMPURITIES FROM RAW MATERIALS BY EXTRACTIVE FERMENTATION LS9,INC. (US) 2009-04-02 US claimed
WO-2009042950-A1 REDUCTION OF THE TOXIC EFFECT OF IMPURITIES FROM RAW MATERIALS BY EXTRACTIVE FERMENTATION LS9, INC. (US) 2009-04-02 WO claimed
CN-121674282-A Method for preparing ultraviolet absorbent by utilizing Gong Pi live cocci Dermacoccus nishinomiyaensis and application 上海交通大学三亚崖州湾深海科技研究院 2026-03-17 CN disclosed
CN-120000749-A Traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis as well as preparation method and application thereof 广州中医药大学第一附属医院 2025-05-16 CN disclosed
WO-2023239842-A1 BETA CARBOLINES AS TOPICAL ANTI-INFLAMMATORY AGENTS FOR APPLICATION TO MUCOUS MEMBRANES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-12-14 WO disclosed
CN-115184533-B LC-MS method for quantitatively detecting golden bell oral liquid 山东宏济堂制药集团股份有限公司 2023-06-20 CN disclosed
CN-115814004-A Medicine composition for treating bone disease 北京朕荣国际生物科技有限公司 2023-03-21 CN disclosed
US-20130172330-A1 Chemokine Receptor Modulators ALTIRIS THERAPEUTICS, INC. (US) 2013-07-04 US disclosed
CN-103083401-A Compound pharmaceutical composition comprising szechwan lovage rhizome extract and caulis sinomenii extract EX RES CT CHINA ACADEMY OF CHINESE MEDICAL SCIENCES 2013-05-08 CN disclosed
US-8313934-B2 Use of hydrophobic solvent immisible from fermentation broth; hydrocarbon biosynthesis of e.g. biodiesel fuels; kits, vehicles, biofuel product LS9, INC. (US) 2012-11-20 US disclosed
US-20090084025-A1 REDUCTION OF THE TOXIC EFFECT OF IMPURITIES FROM RAW MATERIALS BY EXTRACTIVE FERMENTATION LS9,INC. (US) 2009-04-02 US disclosed
WO-2009042950-A1 REDUCTION OF THE TOXIC EFFECT OF IMPURITIES FROM RAW MATERIALS BY EXTRACTIVE FERMENTATION LS9, INC. (US) 2009-04-02 WO disclosed
CN-1364586-A Traditional Chinese medicine compound oral sticking film for coronary heart disease and angina pectoris TIANYIN TEST ANIMAL CT (CN) 2002-08-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172330-A1 Chemokine Receptor Modulators CCR5, CXCR4, ACKR3 BCHE 4400/4885ACHE 4873/4885DYRK1A 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.